Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.155
Peer-review started: May 6, 2015
First decision: July 14, 2015
Revised: July 22, 2015
Accepted: October 13, 2015
Article in press: October 13, 2015
Published online: January 7, 2016
Chronic hepatitis B (CHB) is a global health issue that increases the risk of liver cirrhosis and hepatocellular carcinoma in infected patients. Metabolic syndrome (MetS) is a disease endemic mostly to the developed countries. It is associated with high cardiovascular mortality and morbidity, diabetes mellitus as well as cancer. In this manuscript, we systematically review the published data on the relationship between MetS and CHB infection. Multiple studies have described highly variable correlations between CHB on one hand and MetS, non-alcoholic fatty liver disease and dyslipidemia on the other. No association between CHB and diabetes mellitus or atherosclerosis has been described as of now. The presence of MetS in patients infected with hepatitis B virus increases the risk of fibrosis, cirrhosis and hepatocellular carcinoma. Appropriate lifestyle, but also pharmacological interventions are needed to prevent the development of these complications.
Core tip: Currently, no clear relationship between chronic hepatitis B (CHB) and the prevalence of metabolic syndrome (MetS) could be established, but observations on large patient cohorts reveal some interesting patterns. Surprisingly, male patients with CHB may have lower prevalence of MetS than patients without CHB, but this has not been observed in females. Furthermore, CHB is probably not associated with higher risk of type 2 diabetes mellitus or atherosclerosis. Regarding the clinical outcomes, available data do not sufficiently reveal all of the possible interactions between MetS, its individual components and CHB.